CTNM

Contineum Therapeutics, Inc. Class A Common Stock

13.65

USD

CTNM Earnings Reports

Positive Surprise Ratio

CTNM beat 2 of 8 last estimates.

25%

Next Report

Date of Next Report

May 12, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$0.54

Implied change from Q4 25 (Revenue/ EPS)

+10.20%

Implied change from Q1 25 (Revenue/ EPS)

-12.90%

Contineum Therapeutics, Inc. Class A Common Stock earnings per share and revenue

On Mar 05, 2026, CTNM reported earnings of -0.49 USD per share (EPS) for Q4 25, missing the estimate of -0.41 USD, resulting in a -18.41% surprise. Revenue reached --, compared to an expected 6.12 million, with a -100.00% difference. The market reacted with a +0.51% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an increase of 10.20% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Acumen Pharmaceuticals, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.46

Actual

-$0.41

Surprise

+11.29%

Rani Therapeutics Holdings, Inc. Class A Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.07

Surprise

-2.94%

Spero Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.20

Actual

$0.53

Surprise

+359.80%

Alpha Cognition Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.30

Surprise

-8.93%

Cognition Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.02

Surprise

+76.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

Quantum Biopharma Ltd. Class B Subordinate Voting Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

Actual

-$0.71

Surprise

CollPlant Biotechnologies Ltd Ordinary Shares

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.67

Surprise

-245.72%

FAQ

What were Contineum Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Contineum Therapeutics, Inc. Class A Common Stock reported EPS of -$0.49, missing estimates by -18.41%, and revenue of $0.00, -100% below expectations.

How did the market react to Contineum Therapeutics, Inc. Class A Common Stock's Q4 2025 earnings?

The stock price moved up 0.51%, changed from $13.81 before the earnings release to $13.88 the day after.

When is Contineum Therapeutics, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for May 12, 2026.

What are the forecasts for Contineum Therapeutics, Inc. Class A Common Stock's next earnings report?

Based on 6 analysts, Contineum Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.